MiR-200b inhibits TGF-β1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells

Cell Death and Disease

Volumn 4, Issue 3, 2013, Pages

  Chen, Y ^a,b,c   Xiao, Y ^b,c   Ge, W ^a   Zhou, K ^b,c   Wen, J ^b,c   Yan, W ^b,c   Wang Y, ^b,c   Wang, B ^a   Qu, C ^a   Wu, J ^a   Xu, L ^a   Cai, W ^b,c,d  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute for Pediatric Research   (China)

^c Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

E cadherin; Epithelial mesenchymal transition; Inflammatory bowel disease; Intestinal epithelial cell; MiR 200b; Transforming growth factor beta1

Indexed keywords

CYCLIN D1; MICRORNA 200B; SMAD2 PROTEIN; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; CADHERIN; HOMEODOMAIN PROTEIN; MICRORNA; MIRN200 MICRORNA, HUMAN; SMAD2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENTERITIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; REPRESSOR GENE; UPREGULATION; CELL CULTURE; CROHN DISEASE; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

3' UNTRANSLATED REGIONS; CADHERINS; CELL PROLIFERATION; CELLS, CULTURED; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLIN D1; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; INTESTINAL MUCOSA; MICRORNAS; PROTEIN BINDING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 84875878248     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.22     Document Type: Article

References (44)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317.
2. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
4. Abraham C, Cho JH. IL-23 and autoimmunity: New insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med 2009; 60: 97-110.
5. Feng BS, Chen X, Li P, Zheng PY, Chong J, Cho DB et al. Expression of integrin alphavbeta6 in the intestinal epithelial cells of patients with inflammatory bowel disease. N Am J Med Sci 2009; 1: 200-204.
6. McCole DF. Regulation of epithelial barrier function by the inflammatory bowel disease candidate gene, PTPN2. Ann N Y Acad Sci 2012; 1257: 108-114.
7. Kaser A, Autophagy BlumbergRS. microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 2011; 140: 1738-1747.
8. Siccardi D, Turner JR, Mrsny RJ. Regulation of intestinal epithelial function: A link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 219-235.
9. Petit CS, Barreau F, Besnier L, Gandille P, Riveau B, Chateau D et al. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology 2012; 143: 122-132; e115.
10. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-472.
11. Hering NA, Schulzke JD. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis 2009; 27: 450-454.
12. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008; 14: 401-407.
13. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
14. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S et al. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 1999; 96: 6249-6254.
15. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
16. Scharl M, Weber A, Furst A, Farkas S, Jehle E, Pesch T et al. Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflamm Bowel Dis 2011; 17: 1907-1916.
17. Flier SN, Tanjore H, Kokkotou EG, Sugimoto H, Zeisberg M, Kalluri R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.
18. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-234.
19. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 2005; 33: 6566-6578.
20. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
21. Kubben FJ, Peeters-Haesevoets A, Engels LG, Baeten CG, Schutte B, Arends JW et al. Proliferating cell nuclear antigen (PCNA): A new marker to study human colonic cell proliferation. Gut 1994; 35: 530-535.
22. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7: 1118-1122.
23. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
24. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000; 19: 1745-1754.
25. Dave N, Guaita-Esteruelas S, Gutarra S, Frias A, Beltran M, Peiro S et al. Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J Biol Chem 2011; 286: 12024-12032.
26. Gill JG, Langer EM, Lindsley RC, Cai M, Murphy TL, Kyba M et al. Snail and the microRNA- 200 family act in opposition to regulate epithelial-to- mesenchymal transition and germ layer fate restriction in differentiating ESCs. Stem Cells 2011; 29: 764-776.
27. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S et al. p53 regulates epithelialmesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875-883.
28. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: The importance of apoptosis. J Cell Sci 1994; 107: 3569-3577.
29. Hagiwara C, Tanaka M, Kudo H. Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery. J Gastroenterol Hepatol 2002; 17: 758-764.
30. Iwamoto M, Koji T, Makiyama K, Kobayashi N, Nakane PK. Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 1996; 180: 152-159.
31. Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991; 7: 663-698.
32. Clayburgh DR, Shen L, Turner Jr. A porous defense: The leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84: 282-291.
33. Soderholm JD, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: An inherited defect in mucosal defence? Gut 1999; 44: 96-100.
34. Porras M, Martin MT, Yang PC, Jury J, Perdue MH, Vergara P. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis 2006; 12: 843-852.
35. Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis 2008; 14: 1514-1527.
36. Chen Y, Ge W, Xu L, Qu C, Zhu M, ZhangWet al. miR-200b is involved in intestinal fibrosis of Crohn's disease. Int J Mol Med 2012; 29: 601-606.
37. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-337.
38. Shin JO, Lee JM, Cho KW, Kwak S, Kwon HJ, Lee MJ et al. MiR-200b is involved in Tgfbeta signaling to regulate mammalian palate development. Histochem Cell Biol 2012; 137: 67-78.
39. Kolosova I, Nethery D, Kern JA. Role of Smad2/3 and p38 MAP kinase in TGF-beta1- induced epithelial-mesenchymal transition of pulmonary epithelial cells. J Cell Physiol 2011; 226: 1248-1254.
40. Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao WH et al. Transforming growth factor-beta 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. Oncol Rep 2013; 29: 219-225.
41. Li Y, Kang X, Wang Q. HSP70 decreases receptor-dependent phosphorylation of Smad2 and blocks TGF-beta-induced epithelial-mesenchymal transition. J Genet Genomics 2011; 38: 111-116.
42. Xia W, Li J, Chen L, Huang B, Li S, Yang G et al. MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells. Mol Cell Biochem 2010; 344: 261-266.
43. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-23347.
44. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-549.